Molecular Markers in Fine Needle Aspirates of Thyroid Nodules - Medicare Advantage (Revised)
Effective date
Sep 2, 2025
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has revised its policy for molecular markers in fine needle aspirates of thyroid nodules, effective September 2, 2025. The policy establishes coverage criteria for molecular diagnostic tests like Afirma Genomic Sequencing Classifier used to evaluate indeterminate thyroid nodules when cytopathology cannot determine if nodules are malignant or benign.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
01Before September 2, 2025: Billing team must review and understand coverage requirements for thyroid nodule molecular testing under Humana Medicare Advantage plans.
02Ensure documentation supports medical necessity criteria and that tests are ordered by treating physicians for management of specific medical problems.
03Verify applicable LCD/LCA requirements based on geographic jurisdiction as coverage varies by Medicare Administrative Contractor region.
Codes mentioned
81546
Original notice
Molecular Markers in Fine Needle Aspirates of Thyroid Nodules - Medicare Advantage (Revised)
mcp.humana.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.